KR20140124952A - Composition for controlled release of drugs comprising amniotic membrane-alginate gel complex, and preparing method thereof - Google Patents

Abstract

The present invention relates to a composition for controlled release of drugs, which comprises an amniotic membrane (AM) carrying pharmaceutically acceptable salt; and alginate gel attached to the AM as a barrier, wherein the alginate gel contains alginate and calcium, and the calcium is cross-linked to the alginate. In the composition for controlled release of drugs according to the present invention, the alginate and Ca^2+ are cross-linked so as to form gel of a strong net structure, and this alginate gel is attached to the AM carrying the drugs as the role of a barrier. Therefore, the composition can control release of the drugs carried on the AM by concentration of the calcium and/or concentration of the alginate, whereby can be usefully applied to therapeutic agents for treatment of eye disease.

Description

Technical Field [0001] The present invention relates to a drug-controlled-release type combined preparation comprising amniotic membrane-alginate gel complex and a preparation method thereof, and a preparation method thereof. BACKGROUND ART [0002]

More particularly, the present invention relates to a drug controlled release type combined preparation comprising amniotic membrane-alginate gel complex and a preparation method thereof.

Ophthalmic drug delivery is one of the most attractive and challenging areas of pharmacy. Among the various methods of ophthalmic drug delivery, hydrogels are usually used to treat a variety of ocular diseases. Hydrogels are frequently used in wound dressings and drug carriers in the biomedical field. Wound dressings should provide a moist environment to facilitate recovery. Most wound care products provide these conditions (Winter GD, 1962. Formation of the scab and the rate of epithelization of superficial wounds in Nature 193, 293-294.). In recent years, hydrogels have received considerable attention as a way to improve the performance of control delivery systems because these polymers have been found to be optimal for absorbent surfaces in order to prolong the residence time, (Bourlais CL, Acar L., Zia H., Sado PA, Needham T., Leverge R., 1998. Ophthalmic drug delivery systems recent advances. Prog. Retin. Eye Res 17, 33-58.).

Among them, sodium alginate is a polymer which has been widely used not only in food but also in other industries such as pharmacy and biomedical treatment because of the characteristic characteristic of cation-induced gelation. More specifically, sodium alginate , Monovalent salts of alginic acid consisting of 4-linked? -D-mannuronic acid (M) and? -L-glucuronic acid (G) units and has a structure represented by the following formula (1).

[Chemical Formula 1]

Such sodium alginate has some inherent properties such as non-toxicity, biocompatibility, biodegradability and hydrophilicity, and is relatively low in price as well as in ionic gels in mild conditions (ionotropic gels) are believed to be important biopolymers in biomedical applications such as tissue engineering, drug delivery systems, scaffolds for cell encapsulation and transplantation.

Amniotic membrane (AM), on the other hand, is a thin membrane surrounding the fetus, including the innermost placenta layer, and more specifically three layers of epithelial (monolayer), basement membrane and avascular stromal matrix Lt; / RTI > The epithelium is attached to a continuous basement membrane on a thin avascular stromal matrix, and the AM thickness varies from 0.02 mm to 0.5 mm. Amniotic membrane (AM) also contains no blood vessels, no direct blood supply, and has a physiologically active substance, including vasoactive peptide, growth factor, and cytokine, (Cunningham F. 2001. Williams obstetrics.21 ed. Slock, London.), Barriers and drug storage functions have also been reported (Resch MD, Resch BE, Cszmazia E., Imre L., Nemeth J., Szabo-Revesz P., Csanyi E., 2011. Drug reservoir function of human amniotic membrane. J. Ocul. Pharmacol. Th. 27,323-326.). Amniotic membrane (AM) has been used extensively as a graft in ocular surface grafting. Amniotic membrane transplantation (AM) has been implicated in HSK (herpes stromal keratitis), perforation in corneal ulcer and keratitis, pterygium, And Stevens-Johnson syndrome. ≪ Desc / Clms Page number 2 >

As described above, with the increasing interest in ophthalmic drug delivery, provision of agents for controlling the release rate of drugs using amniotic membrane and alginate gels has become an important issue, This is not the case.

The present invention is such a drug that alginate gel been made to solve the problems of the prior art, and an alginate and cross-linking (cross linking) with Ca ²⁺ form a gel (gel), such as a sturdy net organization, such as the Controlled release type composite preparation capable of controlling release of the drug loaded on the amniotic membrane by the concentration of calcium and / or the concentration of alginate by acting as a barrier by adhering to the amniotic membrane mounted thereon. Purpose.

It is another object of the present invention to provide a method for producing the drug-controlled-release combination preparation.

However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.

The present invention relates to amniotic membrane carrying a hydrophilic drug or a pharmaceutically acceptable salt thereof; And an alginate gel attached to the amniotic membrane as a barrier, wherein the alginate gel comprises alginate alone or alginate and calcium, the calcium being cross-linked to alginate, And a pharmaceutically acceptable salt thereof.

In one embodiment of the present invention, the controlled release of the hydrophilic drug is characterized by being controlled by the concentration of calcium and / or the concentration of alginate.

In another embodiment of the present invention, the hydrophilic drug is a drug for treating ophthalmic diseases.

In still another embodiment of the present invention, the medicament for treating ophthalmic diseases is selected from the group consisting of an antibiotic, an anti-inflammatory agent, an epithelial growth factor (EGF), and a growth factor.

In another embodiment of the present invention, the antibiotic is vancomycin.

According to the present invention,

(1) preparing a mixed solution by mixing and stirring sodium alginate and a plasticizer in a solvent;

(2) injecting the mixed solution into a mold and drying to prepare a gel;

(3) immersing the gel in a calcium chloride solution to crosslink alginate and calcium; And

(4) a step of adhering an amniotic membrane on which the hydrophilic drug or its pharmaceutically acceptable salt is loaded on the cross-linked gel gel.

In one embodiment of the present invention, the plasticizer is glycerin.

Drug controlled release combination preparations according to the present invention the alginate is Ca ^{2 +} and cross-linking (cross linking) to form a gel (gel), such as a sturdy net tissue, and this alginate gel attached to the drug has been mounted amniotic membrane barrier it is expected that the controlled release of the drug loaded on the amniotic membrane can be controlled by the concentration of calcium and / or the concentration of alginate, thereby making it useful as an agent for the treatment of ophthalmic diseases.

1 is a graph showing the swelling property of an alginate gel according to the concentration of sodium alginate (SA).
Fig. 2 is a graph showing the results of confirming the swelling property of the alginate gel according to the concentration of calcium chloride. Fig.
3 is a graph showing the drug release profile of the alginate gel according to the concentration of sodium alginate (SA).
4 is a graph showing the drug release profile of the alginate gel according to the concentration of calcium chloride.
FIG. 5 is a graph showing the drug release profile results of alginate gel according to vancomycin (VCM) concentration. FIG.
6 is a diagram showing the drug release profile results of the amniotic membrane-alginate gel complex to the concentration of sodium alginate (SA).
FIG. 7 shows the drug release profile results of the amniotic membrane-alginate gel complex according to the concentration of calcium chloride. FIG.
8 is a diagram showing a drug release profile result from amniotic membrane (AM) alone on which vancomycin is loaded.
9 is a view showing a result of observation of a cross-section of amniotic membrane-alginate gel composite through a high-resolution microscope.

Hereinafter, the present invention will be described in detail.

The present invention relates to amniotic membrane carrying a hydrophilic drug or a pharmaceutically acceptable salt thereof; And an alginate gel attached to the amniotic membrane as a barrier, wherein the alginate gel comprises alginate alone or alginate and calcium, the calcium being cross-linked to alginate, And a pharmaceutically acceptable salt thereof.

The term "controlled release" as used herein means that the release of the drug is delayed, extended, sustained, prevented, and / or prolonged .

Drug controlled release combination preparations according to the present invention the alginate is Ca ^{2 +} and cross-linking (cross linking) to form a gel (gel), such as a sturdy net tissue, and this alginate gel attached to the drug has been mounted amniotic membrane barrier By acting as a barrier, it is possible to control the controlled release of the drug loaded on the amniotic membrane, and more specifically the controlled release of the drug loaded on the amniotic membrane can be controlled by the concentration of calcium and / or the concentration of alginate . At this time, the hydrophilic drug that can be used is preferably a drug for treating ophthalmic diseases, and more preferably, it can be selected from the group consisting of an antibiotic, an anti-inflammatory agent, an epithelial growth factor (EGF), and a growth factor.

In the present invention, "hydrophilic drug" refers to a certain degree of solubility in an aqueous medium and represents a drug that is in contrast to a lipophilic drug. In particular, the hydrophilic drug used in the present invention has a high solubility as defined in the BCS. Such hydrophilic drugs can be used in the form of pharmaceutically acceptable salts, and the term pharmaceutically acceptable salts as used herein refers to those salts which do not cause serious irritation to the organism to which the compound is administered and impair the biological activity and properties of the compound ≪ / RTI >

Pharmaceutically acceptable salts include acid addition salts formed by pharmaceutically acceptable free acids. Acid addition salts include those derived from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid, and aliphatic mono- and dicarboxylates, phenyl-substituted alkanoates, hydroxyalkanoates, Dioleate, aromatic acid, aliphatic and aromatic sulfonic acids. Such pharmaceutically innocuous salts include, but are not limited to, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate chloride, bromide, Butyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, succinate, maleic anhydride, maleic anhydride, , Sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, Methoxybenzoate, phthalate, terephthalate, benzene sulfonate, toluene sulfonate, chlorobenzene sulfide Sulfonate, methanesulfonate, propanesulfonate, naphthalene-1-sulphonate, naphthalene-1-sulphonate, , Naphthalene-2-sulfonate, or mandelate.

The acid addition salt according to the present invention can be prepared by a conventional method, for example, by dissolving a hydrophilic drug in an excess amount of an aqueous acid solution and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile . By heating the same amount of the hydrophilic drug and the acid or alcohol in water, and then evaporating and drying the mixture, or by suction filtration of the precipitated salt.

In addition, bases can be used to make pharmaceutically acceptable metal salts. The alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the drug in an excess amount of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and evaporating and drying the filtrate. At this time, it is preferable for the metal salt to produce sodium, potassium or calcium salt. In addition, the corresponding silver salt is obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (e.g., silver nitrate).

Further, according to the present invention,

(1) preparing a mixed solution by mixing and stirring sodium alginate and a plasticizer in a solvent;

(2) injecting the mixed solution into a mold and drying to prepare a gel;

(3) immersing the gel in a calcium chloride solution to crosslink alginate and calcium; And

(4) a step of adhering an amniotic membrane on which the hydrophilic drug or its pharmaceutically acceptable salt is loaded on the cross-linked gel gel.

According to one embodiment of the present invention, a gel-forming solution is prepared by mixing sodium alginate (SA) and glycerin in distilled water, injected into a glass mold (2.54 x 1.5 cm ² ) and dried to form a gel, Alginate gel was prepared, and the alginate gel thus prepared was adhered to amniotic membrane on which the drug (vancomycin) was mounted to produce amniotic membrane-alginate gel complex (see Example 3)

According to another embodiment of the present invention, drug release experiments were conducted on the amniotic membrane-alginate gel composite prepared above. As a result, as the sodium alginate (SA) content and the calcium chloride concentration were decreased, the vancomycin release rate was increased, while vancomycin (See Example 6). ≪ tb >< TABLE >

Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the following examples.

[Example]

Example 1. Experimental preparation

Vancomycin hydrochloride was purchased from CJ Cheiljedang (Ansan, Korea). Sodium alginate (SA) (Manugel LBA) was supplied by FMC Biopolymer (Cork, Ireland), and calcium chloride was obtained from Kanto Chemical Co., Inc (Tokyo, Japan). Amniotic membrane (Amnisite ^TM BA) was supplied by Bioland (Cheonan, Korea) and PBS (Phosphate buffered saline) and HPLC-grade phosphoric acid were purchased from Sigma-Adrich Company ). HPLC-grade acetonitrile was purchased from Burdick and Jackson (Muskegon, MI. USA) and ammonium phosphate (Monobasic) was purchased from Samcheon Chemical (Pyungtaek, Korea). On the other hand, distilled water and deionized water were used for the preparation of all solutions.

Example 2 Preparation of alginate gel

To prepare the alginate gel, a gel-forming solution was first prepared. That is, a gel-forming solution was prepared by mixing sodium alginate (SA), vancomycin (VCM) and glycerin as a plasticizer in distilled water at room temperature, and stirring was continued until the mixture became transparent and completely dissolved. The gel prepared - then poured into a glass mold to form a solution 600μL (2.54 x 1.5 cm ²⁾ was dried for 2 hours at 50 ℃, 110μL solution of calcium chloride was dropped to the glass mold. The crosslinked gel was left at ambient conditions for 30 minutes and then separated from the glass mold. Alginate gels containing various contents of sodium alginate (SA), vancomycin (VCM), glycerin and calcium chloride were prepared by the above method, and the specific contents and concentrations thereof are shown in Table 1 below.

Formulation SA
concentration
(% w / v) VCM amount
added
(% w / v) CaCl ₂
concentration
(% w / v) Glycerin
concentration
(% w / v) F1 2 0.5 10 0.5 F2 3 0.5 10 0.5 F3 4 0.5 10 0.5 F4 3 0.5 5 0.5 F5 3 0.5 20 0.5 F6 3 0.5 30 0.5 F7 3 0.25 10 0.5 F8 3 One 10 0.5

Example  3. Amniotic membrane- Alginate  Gel composite production

To prepare the amniotic membrane-alginate gel complex, first, a drug-free gel-forming solution was prepared. That is, a gel-forming solution was prepared by mixing sodium alginate (SA) with distilled water and glycerin with a plasticizer, where it was continuously stirred until the mixture became transparent and completely dissolved. The prepared gel-forming solution was poured to a 600μL glass mold (2.54 x 1.5 cm ²⁾ was dried for 2 hours at 50 ℃, the dried gel was separated from the glass mold. The alginate gel was then immersed in 5 mL of calcium chloride solution for 30 minutes, at which time the excess calcium chloride solution was removed from the surface by flushing water to produce an alginate gel.

The amniotic membrane (AM) was then cut into 2 x 2 cm ² pieces and immersed in 10 mL of vancomycin (VCM) on a petri dish for 1 hour, then the amniotic membrane (AM) was placed on the alginate gel To prepare an amniotic membrane-alginate gel complex on which the drug was finally mounted.

Example 4. Swelling test of alginate gel

The swelling test of the alginate gel prepared in Example 2 was carried out as follows.

4-1. Confirmation of swelling property of alginate gel according to concentration of sodium alginate (SA)

The crosslinked alginate gels prepared in Example 2 contained common 10% w / v% of calcium chloride and 0.5 w / v% of glycerin and contained sodium alginate (SA) at 2, 3 and 4 w / v% Three alginate gels were mixed with 15 mL of a swelling medium (0.01 M PBS, pH 7.4) maintained at 36 ± 0.5 ° C in a shaking incubator (BS-21, Jay Otec, Taejon, Korea) And immersed in a glass vial containing water. At 5, 10, 15, 30, 60 and 120 minutes, the gel was wiped off excess water and immediately removed from the metered medium and the swelling ratio (moisture uptake) of the crosslinked gel was calculated from the following equation (Zactiti EM, Kieckbusch TG, 2006. Potassium sorbate permeability in biodegradable alginate films: Effects of the antimicrobial agent concentration and crosslinking degree. J. Food. Eng. 77, 462-467) :

Where W _o and W _t are the weights of the dried and swollen films measured at different time zones.

More specifically, Figure 1 (A) shows the hourly swelling profile of each alginate gel with various concentrations of sodium alginate (SA), Figure 1 (B) shows the swelling of each alginate gel at 120 minutes Respectively.

As shown in Fig. 1 (A), the swelling ratios of the respective alginate gels containing various concentrations of sodium alginate (SA) were similar, and similarly, as shown in Fig. 1 (B) And the swelling ratio was about 38%. From the above results, it was found that the amount of sodium alginate (SA) did not significantly affect the swelling profile of the alginate gel.

Rather, the swelling characteristics of the alginate gels are believed to be strongly influenced by the ratio of M (1,4-linked β-D-mannuronic acid) / G (α-L-glulonic acid) ^{2 +} (Qin Y., 2004. Gel swelling properties of alginate fibers, J. Appl. Polym. Sci., 91, 1641-1645). From these results, it can be seen that the gel formed from alginate having a low M / G ratio has a low degree of swelling.

4-2. Determination of swelling property of alginate gel according to calcium chloride concentration

Except that three alginate gels containing 3 w / v% of sodium alginate (SA) and 0.5 w / v% of glycerin in common and containing 5, 10 and 30 w / v% of calcium chloride were used, respectively The experiment was carried out in the same manner as in Example 4-1, and the results are shown in FIG.

More specifically, FIG. 2 (A) shows the swelling profile of each alginate gel with various calcium chloride concentrations, and FIG. 2 (B) shows the swelling ratio of each alginate gel at 120 minutes.

As shown in FIGS. 2A and 2B, it was confirmed that the degree of swelling decreased considerably with an increase in the concentration of calcium chloride, and the swelling ratios of the gel at 120 minutes were 4.9, 38.6, and 126.1%, respectively I could.

From the above results, it can be seen that the swellability of the alginate gel increases with decreasing concentration of calcium, which increases the number of alginate strands that make the egg-box model thicker, Resulting in strong network and interference of water absorption.

Example 5 Drug Release Experiment of Alginate Gel

The drug release experiment of the alginate gel prepared in Example 2 was carried out as follows.

5-1. Determination of drug release profile of alginate gel according to concentration of sodium alginate (SA)

The crosslinked alginate gel prepared in Example 2 contained 10 w / v% of calcium chloride and 0.5 w / v% of the drug and 0.5 w / v% of glycerin and contained sodium alginate (SA) at 2, 3 and 4 w / v% Were immersed in a glass vial containing 15 mL of a swelling medium (0.01 M PBS, pH 7.4) maintained at 36 +/- 0.5 DEG C in a shaking incubator at 80 rpm . 100 [mu] L aliquots were collected at 5, 10, 15, 30, 60 and 120 minute intervals and the same amount of fresh solution was replaced to keep the total volume constant, The reaction mixture was analyzed by high performance liquid chromatography (Breeze 2 HPLC system, Waters, Milford, Mass., USA) and the results are shown in FIG. A mobile phase consisting of 10% acetonitrile (0.01 M monobasic ammonium phosphate, pH 4) at a flow rate of 1 mL / min and a Capcell Pak C18 UG80 column (150 x 4.6 mm, 5 μm particle size, Shiseido, ), Vancomycin (VCM) was eluted in about 4 minutes and the detection wavelength was set at 210 nm.

As shown in Fig. 3, it was confirmed that the increase of the content of the sodium alginate (SA) polymer decreases the rate of drug release from the alginate gel. From the above results, if the number of biopolymers per unit solution volume increases, the number of binding sites for Ca ²⁺ ions also increases, and as a result, a more dense crosslinked gel structure can be formed, Of the total.

5-2. Determination of drug release profile of alginate gel according to calcium chloride concentration

Four alginate gels containing sodium alginate (SA) in an amount of 3 w / v% and a drug commonly containing 0.5 w / v% of glycerin and calcium chloride in amounts of 5, 10, 20 and 30 w / v% , The experiment was carried out in the same manner as in Example 5-1, and the results are shown in FIG.

As shown in FIG. 4, it was confirmed that the release rate of the drug (vancomycin) was increased by the decrease of the calcium chloride concentration as a crosslinking agent. The results are in fact related to the cross-linking density, which means that the density increases with increasing cross-linker concentration, and at high cross-linking density it is very difficult for the drug to be released.

5-3. Depending on the concentration of the drug Alginate Gel  Identify the drug release profile

The three alginate gels commonly containing sodium alginate (SA) 3w / v%, calcium chloride 10w / v% and glycerin 0.5w / v% and vancomycin (VCM) Was used as the catalyst, and the experiment was carried out in the same manner as in Example 5-1, and the results are shown in FIG.

As shown in FIG. 5, when expressed in percent, the drug release profile from the alginate gel according to the drug concentration was not significantly different (FIG. 5A). On the other hand, it was confirmed that the release amount of vancomycin (VCM) per 1 cm ² increases as the amount of the drug added as a gel increases (FIG. 5B).

Example  6. Amniotic membrane- Alginate  Drug Release Experiment of Gel Complex

6-1. Sodium Of alginate (SA)  Amniotic membrane - Alginate  Confirmation of Drug Release Profile of Gel Complex

Each alginate gel containing 10 w / v% of calcium chloride and 0.5 w / v% of glycerin and 2, 3 and 4 w / v% of sodium alginate (SA) in common and 5.0 w / v% vancomycin Alginate gel complex prepared by binding with amorphous amorphous membrane (AM) pieces immersed in 10 ml of a 1: 1 (v / v) solution for 1 hour and Franz-diffusion cell system (FCDV-15, Labfine instruments, Anyang, Korea) Respectively.

More specifically, the amniotic membrane (AM) attached to the alginate gel was mounted within the Franz-diffusion cell system. The effective diffusion surface was 0.636 cm ² . 0.01 M PBS (pH 7.4) was used as the acceptor phase and rotation of the stir bar was set at 450 rpm and performed at 36 ± 0.5 ° C. At time intervals of 5, 10, 15, 30, 60 and 120 minutes, 100 μL of sample was withdrawn from the acceptor phase and replaced with the same amount of fresh solution to keep the total volume constant. The amount of drug released from each sample was analyzed using high performance liquid chromatography (Breeze 2 HPLC system, Waters, USA) and the results are shown in FIG. A mobile phase consisting of 10% acetonitrile (0.01 M monobasic ammonium phosphate, pH 4) at a flow rate of 1 mL / min and a Capcell Pak C18 UG80 column (150 x 4.6 mm, 5 μm particle size, Shiseido, ), Vancomycin (VCM) was eluted in about 4 minutes, the detection wavelength was set at 210 nm, and finally the amount of drug released per 1 cm ² of amniotic membrane (AM) (μg / cm ² ) was calculated.

As shown in FIG. 6, it was confirmed that the decrease of the content of sodium alginate (SA) as a polymer increases the amount of drug released per cm ² of amphoteric (AM) -alginate gel composite loaded with the drug.

6-2. Amniotic membrane - Alginate  Confirmation of Drug Release Profile of Gel Complex

Each alginate gel containing sodium alginate (SA) in an amount of 3 w / v% and glycerin in an amount of 0.5 w / v%, salt and calcium in an amount of 5, 10 and 30 w / v%, and 5.0 w / v% vancomycin (AM) pieces immersed for 1 hour in 10 mL of a solution prepared by dissolving the amphoteric-alginate gel complex prepared in Example 1, The results are shown in Fig.

As shown in FIG. 7, it was confirmed that the increase of the calcium chloride concentration as a crosslinking agent decreased the amount of drug released per 1 cm ² of amphoteric (AM) -alginate gel complex loaded with the drug. From the above results, it can be seen that as the concentration of the calcium chloride solution increases, the thickness of the gel increases, so that when the alginate gel is immersed in the calcium chloride solution, two competitive reactions, namely dissolution of the alginate by the solution and Ca ^It was presumed that the gel was insolubilized due to the formation of a crosslinking bond between ^{2 +} and a carboxyl group. That is, when the concentration of the calcium chloride solution is low, the previous process (alginate dissolution) becomes the dominant factor for decreasing the gel thickness (Pavlath, AE, Voisin, A., Robertson, GH, 1999. Pectin-based biodegradable water insoluble films, Macromol. Symp. 140, 107-113). Conversely, if the calcium chloride solution concentration is high, dissolution by cross-linking can be stopped.

6-3. Amniotic membrane with drug ( AM ) Drug release profile from stand-alone

The release profile of vancomycin (VCM) from the amniotic membrane (AM) alone loaded with 0.01 M PBS in amniotic membrane (AM) slices immersed in 10 mL of 2.5 and 5.0 w / v% vancomycin (VCM) And the results are shown in FIG.

More specifically, Figures 8 (A) and 8 (B) show release profiles of vancomycin (VCM) from the amniotic membrane (AM) using a shaking incubator and a Franz-diffusion cell system, respectively.

As shown in FIG. 8, it was confirmed that the drug release amount from the amniotic membrane (AM) immersed in the higher concentration drug solution was higher than that in the case of immersing in the lower concentration drug solution at the same time. On the other hand, the amount of drug released from the amniotic membrane (AM) using a shaking incubator was about twice that of the Franz-diffusion cell system because amniotic membrane (AM) (AM) was exposed when it was fixed.

Example  7. Amniotic membrane- Alginate  Identification of cross-section of gel composite

(AM) pieces immersed in 10 mL of 5.0 w / v% vancomycin (VCM) solution for 1 hour on alginate gels with concentrations of sodium alginate (SA), calcium chloride and glycerin of 3, 10 and 0.5 w / The amniotic membrane-alginate gel composite thus prepared was dried, immersed in paraffin, cut into blocks, and formed into flakes at 3 μm using a rotary microtome (RM2255, Leica, Bensheim, Germany). The prepared samples were then placed on a slide glass and observed using a high resolution microscope (Olympus BX51, Olympus Cooperation, Tokyo, Japan, and CytoViva Inc., Auburn, AL, USA) Nikon, Tokyo, Japan), and the results are shown in FIG.

As shown in Fig. 9, it was confirmed that the amniotic membrane (AM) was closely attached to the surface of the alginate gel, and the thickness of the gel was about 20 mu m.

It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.

Claims (7)

A amniotic membrane on which a hydrophilic drug or a pharmaceutically acceptable salt thereof is loaded; And
An alginate gel attached to the amniotic membrane as a barrier,
Wherein the alginate gel comprises alginate alone or alginate and calcium, and the calcium is cross-linked to alginate.
The controlled release pharmaceutical composition according to claim 1, wherein the controlled release of the hydrophilic drug is controlled by the concentration of calcium and / or the concentration of alginate.
The drug-controlled release combination preparation according to claim 1, wherein the hydrophilic drug is a drug for treating ophthalmic diseases.
4. The drug-controlled release combination preparation according to claim 3, wherein the medicament for treating ophthalmic diseases is selected from the group consisting of an antibiotic, an anti-inflammatory agent, an epithelial growth factor (EGF), and a growth factor.
5. The drug-controlled release combination preparation according to claim 4, wherein the antibiotic is vancomycin.
(1) preparing a mixed solution by mixing and stirring sodium alginate and a plasticizer in a solvent;
(2) injecting the mixed solution into a mold and drying to prepare a gel;
(3) immersing the gel in a calcium chloride solution to crosslink alginate and calcium; And
(4) A method for preparing a drug-controlled release combination preparation, comprising the step of adhering a amphiprotic membrane loaded with a hydrophilic drug or a pharmaceutically acceptable salt thereof onto the cross-linked gel.
7. The method according to claim 6, wherein the plasticizer is glycerin.

Images